Navigation Links
BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
Date:9/22/2008


Toronto Stock Exchange Symbol: MS

- US$10 million received based on the positive review of interim

analysis for international pivotal multiple sclerosis trial -

EDMONTON, Sept. 22 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it has received the US$10 million milestone payment from its partner, Eli Lilly and Company.

The milestone payment is based on the previously announced positive review of the scheduled interim analysis of the Company's pivotal phase II/III Canadian and European trial (MAESTRO-01) of dirucotide (MBP8298) in patients with secondary progressive MS. The independent Data Safety Monitoring Board (DSMB) for the MAESTRO-01 trial recommended that the trial proceed to completion based on the interim analysis which included efficacy and safety data from the first 200 patients to complete the trial.

To date, BioMS has received a total of US$97 million in payments from Eli Lilly and Company, based on the licensing and development agreement for dirucotide (MBP8298). An additional $400 million in milestone payments are possible under the terms of the licensing agreement, in addition to escalating royalties on sales.

"We are pleased that our partner has recognized the outcome of the interim analysis as a significant positive event," said Kevin Giese, President and CEO of BioMS Medical. "We look forward to completing the MAESTRO-01 trial and reviewing the complete data set in the second half of 2009."

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
2. BioMS Medical to present at UBS Global Life Sciences Conference
3. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
4. BioMS Medical announces its intention to renew a normal course issuer bid
5. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
6. BioMS Medical Announces Second Quarter 2008 Results
7. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
8. BioMS Medical to present at BMO Healthcare Conference
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. BioMS Medical to present at Jefferies Healthcare Conference
11. BioMS Medical to present at 2008 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... REDWOOD CITY, Calif. , Dec. 19, 2014 ... , USA) announced today that they have been ... Technologies 1,2 is a privately held company that ... processing of next generation sequencing (NGS) data for the ... into the Roche Sequencing Unit, and will continue to ...
(Date:12/19/2014)... Today, TiFiber, Inc. ... facility and future company headquarters in Fort Smith, ... materials that safely and effectively control dangerous microorganisms. ... its historic, strong support for manufacturing, but also ... edge, technology-based companies such as TiFiber. , ...
(Date:12/19/2014)... Boston, MA (PRWEB) December 18, 2014 ... software, announced the appointment of Siri Bryant as the ... the new Director of Core Implementations. These two new ... provide outstanding customer service by ensuring that iLab continues ... , “In the last four years, iLab has been ...
(Date:12/19/2014)...  Decision Resources Group finds that the ... moderately through 2023 as the aging population, increasing adoption ... biomaterials all spur procedure volumes. Growth will be particularly ... and India , where ... for a larger proportion of the population. ...
Breaking Biology Technology:Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3
... ... in Eighteen Platform and Poster Sessions. Its EPA-approved technologies will be widely highlighted during ... 24-27 in Monterey, California. , ... Los Angeles, CA (Vocus) May 1, 2010 -- The Adventus Group, a ...
... FREISING-WEIHENSTEPHAN, Germany , April 30, 2010 ... proprietary PRS-110 Anticalin(R),compound, which targets the c-Met receptor, demonstrating ... model. The results provide an,indication that an Anticalin approach ... value in treating cancer. A broad body of,research has ...
... chemistry classes often start off with learning how to ... Mellon University chemistry professor David Yaron, seems to be, ... interesting, you may get to use it later." ... students to design and carry out experiments more like ...
Cached Biology Technology:ADVENTUS Bioremediation Technologies Highlighted at Battelle Symposium. 2ADVENTUS Bioremediation Technologies Highlighted at Battelle Symposium. 3ADVENTUS Bioremediation Technologies Highlighted at Battelle Symposium. 4Pieris Announces Positive Preclinical Data on c-Met Anticalin Drug Program 2Virtual lab wins prestigious prize awarded by Science 2Virtual lab wins prestigious prize awarded by Science 3Virtual lab wins prestigious prize awarded by Science 4
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a leader ... million in Series A1 funding led by UK-based Eurovestech. ... participated in the investment round. "We are ... community adopts next-generation sequencing and seeks new approaches for ... Reid Robison , MD MBA, and CEO of Tute ...
(Date:12/3/2014)... 2014   Marvin Test Solutions , a ... for military, aerospace, and manufacturing organizations, today announced ... TS-900 PXI semiconductor test platform . The ... systems to customers at a fraction of the ... ATE. "Our semiconductor customers asked ...
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... (April 23, 2012) The benefits of breast milk are well ... remains a mystery. A new study in the Journal ... of cancer-fighting TNF-related apoptosis inducing ligand (TRAIL) in human milk, ... , Researchers took samples of colostrum, the first ...
... Biology 2012, Dr. Blake Rasmussen and colleagues presented a ... vs. Whey Protein Ingestion on Muscle Protein Synthesis Following ... that a protein blend (combination of soy, whey and ... muscle. Specifically, the blend of proteins in this study ...
... Tampa, Fla. (April. 23, 2012) Researchers interested ... fat and high cholesterol (HFHC) diet on implanted fetal ... the HFHC diet elevated microglial activation and reduced neuronal ... inflammatory response in the central nervous system, they found ...
Cached Biology News:New study finds a protein combination is best to consume post-workout for building muscle 2Study finds 'Western diet' detrimental to fetal hippocampal tissue transplants 2
... DNA Engine Dyad thermal cycler is ... (PCR). The chassis accommodates a variety ... assemblies), which hold different types and ... graphical programming with point-and-click navigation. Peltier ...
MiniCycler thermal cycler with Hot Bonnet heated lid, holds 25x0.2ml tubes...
For demonstration of Helicobacter pylori...
... FLISP Assay with SR-101 Labeled Substrates ... • Accurately measure serine protease activation ... • B-Bridge's FLISP Kits utilize cell-permeable, ... (FLISPs) to measure chymotrypsin-like activity in ...
Biology Products: